PSMD10 sirna

PSMD10 siRNA (Human)

Cat. Num. AAA8233104

• Gene Names: PSMD10; p28; p28(GANK); dJ889N15.2
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: PSMD10; PSMD10 siRNA (Human); 26S proteasome non-ATPase regulatory subunit 10; 26S proteasome regulatory subunit p28; Gankyrin; p28(GANK; PSMD10 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: PSMD10 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 226

• Applicable Applications for PSMD10 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human PSMD10 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for PSMD10 sirna

siRNA to inhibit PSMD10 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4506217
• NCBI GeneID: 5716
• NCBI Accession #: NP_002805.1
• NCBI GenBank Nucleotide #: NM_002814.3
• UniProt Accession #: O75832; Q5U0B2; Q8IZK9
• Molecular Weight: 16,137 Da
• NCBI Official Full Name: 26S proteasome non-ATPase regulatory subunit 10 isoform 1
• NCBI Official Synonym Full Names: proteasome 26S subunit, non-ATPase 10
• NCBI Official Symbol: PSMD10
• NCBI Official Synonym Symbols: p28; p28(GANK); dJ889N15.2
• NCBI Protein Information: 26S proteasome non-ATPase regulatory subunit 10
• UniProt Protein Name: 26S proteasome non-ATPase regulatory subunit 10
• Protein Family: 26S proteasome non-ATPase regulatory
• UniProt Gene Name: PSMD10
• UniProt Entry Name: PSD10_HUMAN

NCBI Description

This gene encodes a subunit of the PA700/19S complex, which is the regulatory component of the 26S proteasome. The 26S proteosome complex is required for ubiquitin-dependent protein degradation. This protein is a non-ATPase subunit that may be involved in protein-protein interactions. Aberrant expression of this gene may paly a role in tumorigenesis. Two transcripts encoding different isoforms have been described. Pseudogenes have been identified on chromosomes 3 and 20.[provided by RefSeq, Mar 2011]

Uniprot Description

PSMD10: Acts as a chaperone during the assembly of the 26S proteasome, specifically of the PA700/19S regulatory complex (RC). In the initial step of the base subcomplex assembly is part of an intermediate PSMD10:PSMC4:PSMC5:PAAF1 module which probably assembles with a PSMD5:PSMC2:PSMC1:PSMD2 module. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Proteasome complex; Protease

Chromosomal Location of Human Ortholog: Xq22.3

Cellular Component: nucleoplasm; proteasome complex; intermediate filament cytoskeleton; cytoplasm; proteasome regulatory particle; cytosol; nucleus

Molecular Function: protein binding; transcription factor binding

Biological Process: positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle; negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle; positive regulation of cyclin-dependent protein kinase activity; protein polyubiquitination; viral reproduction; apoptosis; negative regulation of transcription from RNA polymerase II promoter; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; regulation of apoptosis; negative regulation of DNA damage response, signal transduction by p53 class mediator; antigen processing and presentation of peptide antigen via MHC class I; cytoplasmic sequestering of NF-kappaB; anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; antigen processing and presentation of exogenous peptide antigen via MHC class I; negative regulation of MAPKKK cascade; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; positive regulation of cell growth; regulation of ubiquitin-protein ligase activity during mitotic cell cycle; inhibition of NF-kappaB transcription factor; positive regulation of protein ubiquitination; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; gene expression; mitotic cell cycle; regulation of amino acid metabolic process; negative regulation of apoptosis; G1/S transition of mitotic cell cycle